Oncology Practice will be on site this coming week at the annual meeting of the Society of Gynecologic Oncology in National Harbor, Md., reporting on the latest evidence for treating ovarian, cervical, and endometrial cancers. Key sessions include presentations on PARP inhibitors, novel radiation technologies, biomarker utilization in gynecologic oncology, rare tumors, and palliative care and survivorship.
The annual meeting begins Sunday, March 12, and our team will provide daily updates on the following presentations and more:
Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2.
Sentinel lymph node biopsy for early cervical cancer: Results of a randomized prospective, multicenter study (Senticol 2) comparing adding pelvic lymph node dissection vs. sentinel node biopsy only.
BRCA1 and RAD51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2.
Cluster analysis of chemotherapy nonresponders for patients with serous epithelial ovarian cancer.
Oncologic outcomes of adjuvant chemotherapy in patients with risk factors after radical surgery in FIGO stage IB-IIA cervical cancer.
Combining whole pelvic radiation with chemotherapy in stage IVB cervical cancer: A novel treatment strategy.
Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma.
Clinical behavior of low-grade serous ovarian carcinoma: An analysis of 714 patients from the Ovarian Cancer Association Consortium (OCAC).
A randomized controlled trial comparing the efficacy of perioperative celecoxib versus ketorolac for perioperative pain control.
Combination therapy with IL-15 superagonist (ALT-803) and PD-1 blockade enhances human NK cell immunotherapy against ovarian cancer.
Reversal of obesity-driven aggressiveness of endometrial cancer by metformin.
A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study.
Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study.
A prospective phase II trial of the listeria-based human papillomavirus immunotherpay axalimogene filolisbac in second- and third-line metastatic cervical cancer: A NRG oncology group trial.
Overall survival in BRCA1 or RAD51C methylated vs. mutated ovarian carcinoma following primary treatment with platinum chemotherapy.
Early palliative care is associated with improved quality of end-of-life care for women with high-risk gynecologic malignancies.
Contemporary recurrence and survival outcomes for stage IB squamous cell carcinoma of the vulva: Time to raise the bar.